0000000000359383

AUTHOR

Invernizzi P.

showing 2 related works from this author

Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry

2016

Portal vein thrombosis may occur in cirrhosis; nevertheless, its prevalence, and predictors are still elusive. To investigate this issue, the Italian Society of Internal Medicine undertook the “Portal vein thrombosis Relevance On Liver cirrhosis: Italian Venous thrombotic Events Registry” (PRO-LIVER). This prospective multicenter study includes consecutive cirrhotic patients undergoing Doppler ultrasound examination of the portal area to evaluate the prevalence and incidence of portal vein thrombosis over a 2-year scheduled follow-up. Seven hundred and fifty-three (68 % men; 64 ± 12 years) patients were included in the present analysis. Fifty percent of the cases were cirrhotic outpatients.…

RegistrieLiver CirrhosisMaleCirrhosisHepatocellular carcinoma030204 cardiovascular system & hematologyGastroenterology0302 clinical medicineEsophageal varicesPrevalenceMedicineProspective StudiesRegistriesProspective cohort studyMultivariate AnalysiVenous ThrombosisPortal VeinAnticoagulants; Esophageal varices; Hepatocellular carcinoma; Liver failure; Splanchnic venous thrombosis; Emergency Medicine; Internal MedicineMiddle AgedPortal vein thrombosisVenous thrombosisSplanchnic venous thrombosis Anticoagulants Liver failure Hepatocellular carcinoma Esophageal varicesSplanchnic venous thrombosisItalyLiverEmergency MedicineFemale030211 gastroenterology & hepatologymedicine.symptomSettore SECS-S/01 - StatisticaHumanmedicine.medical_specialtyLiver CirrhosiSocio-culturaleEsophageal varicesAsymptomatic03 medical and health sciencesAnticoagulants Esophageal varices Hepatocellular carcinoma Liver failure Splanchnic venous thrombosisInternal medicineInternal MedicineHumansAgedHepatologyEsophageal varicebusiness.industryAnticoagulantLiver failureAnticoagulants; Esophageal varices; Hepatocellular carcinoma; Liver failure; Splanchnic venous thrombosis;AnticoagulantsSplanchnic venous thrombosimedicine.diseaseSurgeryProspective StudieSplanchnic venous thrombosis Anticoagulants Liver failure Hepatocellular carcinoma Esophageal varicesMultivariate AnalysisUpper gastrointestinal bleedingComplicationbusinessJournal of Hepatology
researchProduct

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to succ…

2019

Purpose: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. Unlike the well-characterized and easily manageable safety profile of endocrine therapies, adverse events associated with targeted therapies are complex and potentially severe. Their prompt recognition and treatment, crucial for prolonged endocrine sensitivity and survival, may be challenging and requires a multidisciplinary effort and a good knowledge of drug interactions. Methods:…

0301 basic medicineCancer ResearchReviewDiseasechemistry.chemical_compound0302 clinical medicineRibociclibMolecular Targeted TherapyAbemaciclibClinical Trials as TopicDisease ManagementMetastatic breast cancerEverolimuOncologyReceptors Estrogen030220 oncology & carcinogenesisFemaleAdvanced breast cancerReceptors ProgesteroneBreast Neoplasmmedicine.drugHumanmedicine.medical_specialtyNeutropeniaDrug-Related Side Effects and Adverse ReactionsAntineoplastic Agents HormonalProtein Kinase InhibitorBreast NeoplasmsPalbociclibPalbociclib03 medical and health sciencesBreast cancermedicineBiomarkers TumorHumansEverolimusIntensive care medicineAdverse effectProtein Kinase InhibitorsEverolimusbusiness.industrymedicine.diseaseClinical trialAbemaciclib030104 developmental biologychemistryMED/06 - ONCOLOGIA MEDICAbusinessDrug-Related Side Effects and Adverse ReactionAbemaciclib; Advanced breast cancer; Everolimus; Neutropenia; Palbociclib; Ribociclib
researchProduct